

## TABLE OF CONTENTS

<i>TITLE .....</i>	<i>i</i>
<i>THESIS APPROVAL .....</i>	<i>ii</i>
<i>PLAGIARISM-FREE STATEMENT .....</i>	<i>iii</i>
<i>PREFACE .....</i>	<i>iv</i>
<i>TABLE OF CONTENTS .....</i>	<i>vii</i>
<i>LIST OF TABLES .....</i>	<i>x</i>
<i>LIST OF FIGURES .....</i>	<i>xi</i>
<i>LIST OF ATTACHMENTS .....</i>	<i>xii</i>
<i>LIST OF ABBREVIATIONS .....</i>	<i>xiii</i>
<i>ABSTRACT .....</i>	<i>xiv</i>
<i>CHAPTER 1 INTRODUCTION .....</i>	<i>1</i>
A. Background of The Study .....	1
B. Problem Statement .....	4
C. Research Originality .....	5
D. Benefits of The Study .....	6
E. Objectives of the Study .....	7
<i>CHAPTER 2 LITERATURE REVIEW .....</i>	<i>8</i>
A. Literature Review .....	8
1. Human Papillomavirus .....	8
2. HPV-Related Cancer .....	9
3. HPV Vaccination .....	15
4. Pharmacoeconomic Study .....	17

B. Theoretical Basic.....	29
C. Conceptual Framework .....	31
D. Hypothesis.....	32
<i>CHAPTER 3 RESEARCH METHOD.....</i>	<i>33</i>
A. Study Design .....	33
B. Study Variable.....	34
C. Collecting Data Method .....	36
D. Data Analysis .....	38
1. Developing Markov Model .....	38
2. Inputting data into the Markov Model and Cohort Simulation.....	40
3. Model Outcome.....	40
4. Calculation of Incremental Cost Effectiveness Ratio (ICER).....	40
5. Sensitivity Analysis.....	41
F. Study Ethics .....	42
<i>CHAPTER 4 RESULT AND DISCUSSION .....</i>	<i>43</i>
A. Data Acquisition.....	43
B. Developing Markov Model .....	44
C. Input Parameter .....	45
1. Costs .....	45
2. Utility .....	49
3. Transition Probability (TP) .....	50
4. Vaccine Effectiveness .....	54
5. Vaccination Coverage .....	55
6. Recurrence Rate .....	55
7. Discount Rate .....	56
D. Epidemiological/Clinical Outcome.....	57
E. Calculating ICER .....	62

F. Sensitivity Analysis.....	67
1. One-Way (Univariate) Sensitivity Analysis.....	67
2. Probabilistic Sensitivity Analysis .....	72
G. Limitation of Study .....	74
<i>CHAPTER 5 CONCLUSIONS AND RECOMMENDATIONS</i> .....	75
A. Conclusions .....	75
B. Recommendations .....	76
<i>REFERENCES</i> .....	77

## LIST OF TABLES

Table 1. Related prior study .....	5
Table 2. Types of HPV-related Cancer .....	10
Table 3. Types of Perspective in Pharmacoeconomic Study .....	22
Table 4. The Burden of HPV-related Cancer in Indonesia .....	29
Table 5. Transition Probabilities of Many Health States .....	39
Table 6. Data Obtained from Many Sources.....	43
Table 7. Percentage of HPV-related Cancer per Stage .....	46
Table 8. Parameter of costs that included in the model .....	49
Table 9. Health Utility of HPV-Related Cancers.....	50
Table 10. Transition Probabilities from Susceptible to Cancer (tS2C).....	52
Table 11. Transition Probabilities from Cancer to Death (tC2D).....	52
Table 12. Transition Probabilities from Susceptible to Death (tS2D) .....	53
Table 13. Vaccine Effectiveness toward HPV-related Cancers.....	54
Table 14. Parameters used in the Markov model.....	56
Table 15. The Reduction of HPV-Related Cancers Incidence Due to HPV Vaccination.....	58
Table 16. Incremental Cost-effectiveness Ratio (ICER) of HPV vaccination vs No vaccination in girls population .....	64
Table 17. Incremental Cost-effectiveness Ratio (ICER) of HPV vaccination in Girls and Women (G+W) vs Girls Only to Prevent Cervical Cancer ..	65
Table 18. Incremental cost-effectiveness Ratio (ICER) of HPV vaccination in Girls and Women (GW) vs Girls Only to Prevent HPV-related Cancers .....	66

## LIST OF FIGURES

Figure 1. Comparison of HPV related cancers incidence to other cancers in men and women of all ages in the World (estimates for 2020).....	12
Figure 2. Comparison of HPV related cancers incidence to other cancers in men and women of all ages in Indonesia (estimates for 2020) .....	12
Figure 3. Comparison of HPV related cancers mortality to other cancers in men and women of all ages in the world (estimates for 2020) .....	13
Figure 4. Comparison of HPV related cancers mortality to other cancers in men and women of all ages in Indonesia (estimates for 2020) .....	13
Figure 5. Conceptual Framework.....	31
Figure 6. Markov Model .....	38
Figure 7. Study Procedures .....	42
Figure 8. Predicted annual cases of HPV-related cancers prevented by HPV vaccination in girls .....	60
Figure 9. Predicted annual cases of HPV-related cancers prevented by HPV vaccination in women.....	62
Figure 10. Tornado Diagram for HPV vaccination compared with no vaccination in girls to prevent cervical cancer.....	68
Figure 11. Tornado Diagram for HPV vaccination compared with no vaccination in girls to prevent HPV-related cancers .....	69
Figure 12. One-way Sensitivity Analysis HPV vaccination for cervical cancer prevention in girls+women (G+W) vs girls only .....	70
Figure 13. One-way Sensitivity Analysis HPV-related Cancers Prevention in Girls+Women vs Girls Only .....	71
Figure 14. Probabilistic Sensitivity Analysis (PSA) of HPV Vaccination vs no vaccination in Girls .....	72
Figure 15. Probabilistic Sensitivity Analysis (PSA) of HPV Vaccination girls+women vs girls only to prevent cervical cancer.....	73

## LIST OF ATTACHMENTS

Attachment 1. Ethical Clearance.....	84
Attachment 2. Direct medical cost for anal cancer .....	85
Attachment 3. Direct medical cost for cervical cancer .....	87
Attachment 4. Direct medical cost for hypopharyngeal cancer .....	89
Attachment 5. Direct medical cost for laryngeal cancer .....	91
Attachment 6. Direct medical cost for lip and oral cavity cancer.....	93
Attachment 7. Direct medical cost for oropharyngeal cancer.....	95
Attachment 8. Direct medical cost for penile cancer .....	97
Attachment 9. Direct medical cost for vaginal cancer .....	99
Attachment 10. Direct medical cost for vulvar cancer .....	101
Attachment 11. Estimated number of new cases in 2020 .....	103
Attachment 12. Estimated number of deaths in 2020 .....	108
Attachment 13. Death all causes .....	113
Attachment 14. Parameters in tornado diagram for girls (Cervical Cancer).....	114
Attachment 15. Parameters in tornado diagram for girls (HPV-related Cancer)	114
Attachment 16. Parameters in tornado diagram for Girls and Women (G+W) vs Girls (Cervical Cancer).....	115
Attachment 17. Parameters in tornado diagram for Girls and Women (G+W) vs Girls (HPV-related cancers) .....	115
Attachment 18. Thesis Summary .....	116
Attachment 19. Ringkasan Tesis.....	117

## LIST OF ABBREVIATIONS

ACIP	Advisory Committee on Immunization Practices
ASR	Age-Standardized Rate
BPJS	Badan Penyelenggara Jaminan Kesehatan
CEA	Cost-Effectiveness Analysis
CEP	Cost-Effectiveness Plane
CET	Cost-Effectiveness Threshold
CI	Confidence Interval
CUA	Cost Utility Analysis
FDA	Food and Drug Administration of the United States
GAVI	The vaccine alliance, International organization of Vaccine
GDP	Gross Domestic Product
GNV	Gender-Neutral Vaccination
HIC	High-Income Country
HIV	Human immunodeficiency virus
HPV	Human Papillomavirus
HRQOL	Health Related Quality of Life
HTA	Health Technology Assessment
ICER	Incremental Cost-Effectiveness Ratio
IDR	Indonesian Rupiah
LMIC	Low-Middle-Income Country
PSA	Probabilistic Sensitivity Analysis
QALY	Quality-Adjusted Life Year
UNICEF	United Nations International Children 's Emergency Fund
WHO	World Health Organization
WTP	Willingness to Pay